First CAR T-cell trial for myeloma a success for Andrew
Andrew was the first person in Western Australia to have the life-changing therapy.
- Clinical trials
- Myeloma
- Treatments and side-effects
Tag: Treatments and side-effects
New international trial for amyloidosis
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
- Amyloidosis
- Clinical trials
- Research
- Treatments and side-effects
Expert Series: Dr Piers Blombery on genomic testing
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
- Hodgkin lymphoma
- Interviews with experts
- Myeloma
- Non-Hodgkin lymphoma
- Research
- Treatments and side-effects
PBAC update on new MDS & CMML treatment
The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.
- Myelodysplastic syndromes
- Treatments and side-effects
Improving infection prevention with drug optimisation
Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Research
- Treatments and side-effects
PBAC to consider three lymphoma drugs
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Treatments and side-effects
Expert Series: AProf. Michael Dickinson discusses CAR T-cell therapy
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
- Acute lymphoblastic leukaemia
- Chronic lymphocytic leukaemia
- Hodgkin lymphoma
- Interviews with experts
- Myeloma
- Non-Hodgkin lymphoma
- Research
- Treatments and side-effects
PBAC update on two myeloma drugs
These two myeloma drugs were not recommended for listing on the PBS.
- Myeloma
- Treatments and side-effects
AL amyloidosis trials due to open this year offer “new hope”
Two clinical trials will open later this year for newly diagnosed patients with AL amyloidosis with moderate to severe cardiac disease.
- Amyloidosis
- Clinical trials
- Research
- Treatments and side-effects
Daratumumab – first new myeloma agent PBAC-recommended in years
The drug has received a positive recommendation for PBS listing.
- Advocacy and policy
- Myeloma
- Treatments and side-effects
